RIXUBIS

Indicated For

hemophilia B

About This Medication

# Takeda Patient Support Co-Pay Assistance Program Patient Guide: How to Get RIXUBIS at Low or No Cost ## About RIXUBIS (Nonacog Gamma) RIXUBIS is a recombinant coagulation factor IX replacement therapy used to prevent and treat bleeding episodes in patients with hemophilia B of all ages.[1][2] The medication works by providing a functional version of the factor IX protein, helping to restore normal blood clotting.[10] RIXUBIS can be used for routine prophylaxis (preventive therapy) to reduce bleeding frequency, as on-demand treatment for active bleeds, and to manage bleeding during surgery.[1][5] The medication is administered as an intravenous infusion, and many patients learn to self-infuse with training from their healthcare provider or hemophilia treatment center.[4] ## Who Qualifies for This Program The Takeda Patient Support Co-Pay Assistance Program is designed to help **commercially insured patients** reduce their out-of-pocket costs for RIXUBIS. This program is specifically for patients who have private health insurance coverage. If you meet the following criteria, you may be eligible: - You have been prescribed RIXUBIS by your healthcare provider - You have active commercial health insurance coverage - You are experiencing financial difficulty affording your co-pays or coinsurance - You are a U.S. resident ## Income Eligibility While specific income thresholds for this co-pay assistance program are not publicly detailed, Takeda's patient support programs generally consider household income when determining eligibility. The program focuses on commercially insured patients who may struggle with medication costs despite having insurance. For detailed information about income-based eligibility, contact Takeda directly at **(888) 229-8379**. A patient support specialist can review your specific financial situation and determine your eligibility. ## Insurance Requirements This program is exclusively for **commercially insured patients**. You must have active private health insurance that covers RIXUBIS. The program works alongside your existing insurance to help reduce your personal financial responsibility. If you are uninsured or covered by Medicare/Medicaid, you may qualify for different Takeda patient assistance programs. Contact Takeda to explore alternative options. ## How to Apply ### Step 1: Gather Your Information Before applying, have the following information ready: - Your insurance card and policy details - Your prescription for RIXUBIS - Your healthcare provider's contact information - Your household income information (for eligibility verification) - Your Social Security number (for identity verification) ### Step 2: Apply Online The Takeda Patient Support Co-Pay Assistance Program accepts applications through their online portal. Visit Takeda's patient support website to access the application form. The online application is the primary method for submitting your request. ### Step 3: Phone Application Option If you prefer to apply by phone or need assistance completing the online application, you can call **(888) 229-8379**. A patient support representative will guide you through the application process and answer any questions. ### Step 4: Submit Required Documentation You will need to provide documentation to verify your eligibility. While specific required documents are not detailed in the program information, typical documentation may include: - Proof of insurance coverage - Recent pay stubs or income verification - Tax return (if self-employed) - Proof of residency Ask the patient support representative which documents are required for your specific situation. ### Step 5: Await Approval After submitting your application and documentation, Takeda will review your request. While specific processing timelines are not publicly available, most co-pay assistance programs process applications within 5-10 business days. You will be notified of your approval status by mail or phone. ## Timeline and Delivery Once approved, the program will work with your pharmacy and insurance company to reduce your co-pay or coinsurance at the point of sale. In many cases, you may see the benefit applied at your next pharmacy visit. If you need RIXUBIS urgently, inform the patient support team, and they may be able to expedite the process. ## What If Your Application Is Denied? If your application is denied, you have several options: 1. **Request reconsideration**: Contact Takeda to understand the reason for denial and ask if additional information could support your eligibility. 2. **Explore alternative programs**: Takeda may have other patient assistance programs for uninsured or underinsured patients, or for those who don't qualify for the co-pay program. 3. **Contact your healthcare provider**: Your doctor's office may have resources or alternative medications to discuss. 4. **Seek nonprofit assistance**: Organizations like the National Hemophilia Foundation may offer additional financial resources or guidance. ## Reauthorization and Refills While specific reauthorization requirements are not detailed, most co-pay assistance programs require annual recertification. You may need to reapply or provide updated financial information annually to maintain your benefits. Takeda will notify you if reauthorization is needed. For ongoing refills, once approved, the program typically continues to apply your benefit at the pharmacy with each prescription. Contact Takeda if you have questions about refill coverage. ## Important Disclaimer This guide provides general information about the Takeda Patient Support Co-Pay Assistance Program for RIXUBIS. Program details, eligibility requirements, and benefits may change. For the most current and accurate information, contact Takeda directly at **(888) 229-8379** or visit their official patient support website. This program is not insurance and does not replace your health insurance coverage. Always consult with your healthcare provider about your treatment options and financial assistance programs.

Program information last verified: March 30, 2026